Rockwell Medical, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. The filing is an annual report, not a standalone fourth-quarter report; quarterly results are not clearly provided in the supplied text.
Business context
Rockwell develops, manufactures and distributes hemodialysis products. Its core business is acid and bicarbonate concentrates, which generated approximately 98.4% of 2022 revenue. The company describes itself as the second-largest U.S. supplier in this market. Triferic, its ferric pyrophosphate citrate (FPC) product, is no longer being commercialized in the United States; the company continues to support international partners.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Net sales | $72.8 million | $61.9 million |
| Gross profit (loss) | $4.1 million; 5.6% margin | ($2.4 million); (3.9%) margin |
| Operating loss | ($16.8 million) | ($30.3 million) |
| Net loss | ($18.7 million) | ($32.7 million) |
| Net loss per share | ($1.89) | ($3.83) |
| Net cash used in operating activities | ($17.4 million) | ($33.5 million) |
Revenue increased 17.6%, principally from the DaVita contract amendment and higher pricing to other customers. Gross profit improved by $6.5 million, although increased distribution costs and lower volumes were headwinds. Research and product development expense fell to $3.1 million from $6.8 million, and selling and marketing expense fell to $2.1 million from $5.7 million, reflecting program pauses, lower Triferic marketing and workforce reductions. General and administrative expense was $15.6 million, broadly flat year over year.
At year-end, cash and cash equivalents were $10.1 million and available-for-sale investments were $11.4 million, or $21.5 million combined. Working capital was $17.6 million and stockholders’ equity was $14.1 million. The balance sheet shows term-loan principal of $10.0 million, net of issuance costs and discount, split between current and long-term liabilities. Interest expense was $1.9 million. Financing cash inflows were $16.6 million, including equity proceeds, partially offset by debt and short-term-note repayments.
Material changes and strategy
- Rockwell amended its DaVita supply agreement in April 2022, including a price increase effective May 1 and pass-through of certain inflation-related costs, subject to a cap. DaVita represented 46% of 2022 concentrate sales; its purchase agreement is scheduled to expire December 31, 2023.
- In November 2022, Rockwell reacquired its U.S. hemodialysis-concentrate distribution rights from Baxter and terminated their exclusive distribution agreement. Rockwell assumed responsibility for transitioning and serving former Baxter customers; certain transition services continued through March 31, 2023. The company expects direct distribution and pricing control to support profitability, but results depend on retaining customers and managing delivery costs. The reacquisition fee amount is not stated in the supplied text.
- Rockwell discontinued its U.S. Triferic and Triferic AVNU New Drug Applications after limited adoption, unfavorable reimbursement and continuing commercial losses. The products were not discontinued for safety reasons. FPC home-infusion development was put on hold after study results indicated further reformulation and a Phase 2 study would require significant resources. The path forward for FPC in acute heart failure remained under review.
- The stated strategy is to grow concentrates and international Triferic partnerships, contain costs and reach profitability before considering further capital-intensive development.
Outlook, risks and unusual items
Management said it expected available resources to fund operations for at least 12 months from the filing date, assuming execution of its plans for pricing, customer growth, margin improvement and cost controls, with additional financing available if needed. The filing nevertheless records that the company’s losses and cash use initially raised substantial doubt about its ability to continue as a going concern; management concluded its plans alleviated that doubt. The auditor identified the going-concern evaluation as a critical audit matter, not as a separate opinion or qualification.
- High customer concentration, particularly DaVita, creates exposure to contract renewal, volume declines and pricing limits. Losing DaVita could remove approximately half of current concentrate volume.
- Inflation, raw-material and fuel shortages, labor costs and transportation expenses may compress margins; the company may be unable to pass all increases to customers.
- The Innovatus loan is secured by substantially all company and Rockwell Transportation assets and contains liquidity, revenue and other covenants. Rockwell prepaid $5.0 million in November 2022 and received interest-only payment terms through September 2023, when scheduled debt payments were to resume. The company reported covenant compliance at year-end.
- Financing included $15.0 million of DaVita preferred stock and approximately $14.9 million net proceeds from a registered offering and private placement. Potential dilution is substantial: the filing reported 19.2 million shares potentially issuable from options, preferred stock, warrants and other awards at year-end, compared with 12.2 million common shares outstanding.
- A routine FDA inspection resulted in four Form 483 observations classified as Voluntary Action Indicated; management reported corrective follow-up. The FDA also indicated a completed Class III concentrate recall might be reclassified as Class II. The SEC informed the company in January 2022 that it did not intend to recommend enforcement action following its investigation.
- No numerical revenue, earnings or cash-flow guidance is provided. The business remains loss-making and dependent on successful execution and potential access to additional capital.
Important facts for investors to verify
- Whether Rockwell retained former Baxter customers after taking over distribution, and the resulting revenue, margins and delivery costs.
- DaVita contract renewal status, pricing and volume trends, cost-pass-through limits, and compliance with the agreement’s minimum-cash requirement.
- Actual cash burn and financing needs versus management’s 12-month liquidity assessment, including the timing and terms of any additional funding.
- Debt repayment schedule, covenant headroom and the effect of resuming scheduled payments after September 2023.
- Potential dilution from outstanding warrants and convertible preferred stock, including subsequent exercises or conversions.
- Progress of international Triferic partnerships and any material FDA follow-up concerning the inspection observations or recall classification.